Results 91 to 99 of about 16,901 (99)

Evaluation of the impact of low activity imaging in [¹¹C]-(+)-PHNO and [¹¹C]UCB-J PET-MR scans. [PDF]

EJNMMI Phys
Ribeiro D, Hallett W, Howes O, McCutcheon R, Nour MM, Nutt D, Erritzoe D, Agnorelli C, Husbands S.   +8 more
europepmc   +1 more source

Correction to "Understanding time-activity curve and time-integrated activity variations in radiopharmaceutical therapy challenge: Experience and results". [PDF]

Med Phys
europepmc   +1 more source

UAB/SNMMI Nuclear Medicine Therapy Intensive: Advancing Competence and Innovation in Radiopharmaceutical Therapy. [PDF]

J Nucl Med Technol
Glasgow KW, Brady AB.
europepmc   +1 more source

EVALUATION OF THE RADIOISOTOPIC SYNOVECTOMY PROTOCOL IN PATIENTS WITH HEMOPHILIA. [PDF]

Acta Ortop Bras
Martins MDS, Ricciardi JBDS, Santos AO, Ozelo MC, Pagnano RG, Sakuma ETI.   +5 more
europepmc   +1 more source

Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting. [PDF]

RSC Adv
Rahimi MN, Pinson JA, Hilton-Proctor J, Van Zuylekom J, Blyth B, Roselt PD, Haskali MB.   +6 more
europepmc   +1 more source

Assessment of quality control and effect of radiolysis on the in vivo biodistribution of [¹⁷⁷Lu]Lu-PSMA-I&T. [PDF]

EJNMMI Radiopharm Chem
Hooijman EL, Ntihabose CM, Koolen SLW, Handula M, Beekman S, Stuurman D, de Ridder C, de Jong JR, van de Merbel JRJP, Rook N, Aalbersberg EA, Ververs TFFT, Laverman P, Hendrikx JJMA, de Blois E.   +14 more
europepmc   +1 more source

Tumour Microenvironment-Informed Radiotheranostics: Why and How Nuclear Medicine Could Advance Precision Oncology in the Decade Ahead. [PDF]

Pharmaceuticals (Basel)
Pandya K, Lin Z, Wadsak M, Wang J, Shi K, Seifert R.   +5 more
europepmc   +1 more source